Blog
    Regulatory UpdateFor PhysiciansApril 20, 2026

    FDA peptide status and clinical safety signals

    Review FDA 503A compounding status for BPC-157 and TB-500, plus safety signals for Semaglutide including gastric emptying and NAION risk data.

    Clinical Question

    What is the current regulatory status of commonly used peptides under FDA 503A/503B guidelines, and what safety signals have been identified in clinical trials and post-marketing surveillance?

    Evidence Snapshot

    • Regulatory Surveillance: Multiple peptides including BPC-157, TB-500, and several GHRH analogs were classified as Category 2 (significant safety risk) as of September 2023.
    • Compound Withdrawal: Nominations for AOD-9604, CJC-1295, Ipamorelin, and Selank were withdrawn or removed from list consideration in September 2024.
    • Safety Data (Semaglutide): Strong signals for GI distress (Nausea/Vomiting) and delayed gastric emptying; emerging signals for NAION and pulmonary aspiration.
    • Clinical Outcomes: Phase III trials demonstrate significant weight loss for approved GLP-1/GIP receptor agonists, while certain thymic peptides failed to show mortality benefits in sepsis.

    What the Research Shows

    FDA regulatory data as of March 2026 indicates a restrictive environment for several therapeutic peptides. BPC-157, GHK-Cu, TB-500, and Semax are currently classified as Category 2 substances under Section 503A, meaning they are considered to pose significant safety risks and are ineligible for routine compounding. The FDA specifically cites immunogenicity concerns and a lack of safety data for BPC-157 and TB-500. Furthermore, CJC-1295 and Ipamorelin have had their nominations withdrawn or removed from the list as of September 2024, with the FDA citing safety issues such as increased heart rate for CJC-1295.

    In pharmacovigilance, Semaglutide has a robust safety profile through 187,757 GLP-1 receptor agonist reports. Strong signals are confirmed for nausea, vomiting, and delayed gastric emptying. The latter has led to a 2025 label update for Ozempic regarding pulmonary aspiration risks during general anesthesia. Emerging signals include 96 cases of Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) as of December 2024, which triggered a formal EMA review in January 2025.

    Clinical trials highlight varying efficacy. Trial NCT03548935 (STEP 1) and NCT04184622 (SURMOUNT-1) showed weight loss of 14.9% and 22.5% for semaglutide and tirzepatide, respectively. Conversely, Thymosin Alpha-1 trial NCT02867267 reported negative results for mortality reduction in sepsis.

    Mechanism

    According to regulatory and clinical data, the mechanisms of concern or action include:

    • Immunogenicity: Cited by the FDA as a primary risk factor for BPC-157, TB-500, GHK-Cu, and GHRP-2.
    • Gastric Dynamics: Semaglutide causes delayed gastric emptying, which contributes to its gastrointestinal profile and potential for pulmonary aspiration.
    • Cardiovascular: CJC-1295 is associated with an increased heart rate.
    • Metabolic: GLP-1 and GIP receptor agonists (Semaglutide, Tirzepatide, Retatrutide) produce dose-dependent weight loss and cardiovascular risk reduction (20% MACE reduction for semaglutide).

    Limitations of the Evidence

    There is a notable lack of human exposure data for several peptides including TB-500 and BPC-157. While Thymosin Alpha-1 and Selank are approved in other jurisdictions (such as Russia or internationally as Zadaxin), they lack FDA approval in the United States. Safety signals for suicidal ideation under semaglutide therapy are currently under evaluation, though current data do not support a risk higher than background levels. Additionally, many peptides investigated (such as GHK-Cu) are not FDA-approved as injectable drugs, limiting the available clinical safety database.

    Clinical Takeaway

    The regulatory landscape for peptides is tightening, with several substances removed from compounding eligibility due to safety risks and immunogenicity concerns. For approved GLP-1 agonists, clinicians must monitor for gastrointestinal-related dehydration, pancreatitis, and emerging pre-surgical risks related to delayed gastric emptying. Non-FDA approved peptides currently lack the human safety data required for routine clinical use in the United States.

    Sources

    1. FDA Regulatory Status Records (BPC-157, Thymosin Alpha-1, TB-500, AOD-9604, CJC-1295, Ipamorelin, Selank, Semax, GHK-Cu, GHRP-2).
    2. FAERS Safety Signals (Semaglutide reports through 2023; NAION cases through Dec 2024).
    3. Clinical Trial Records: NCT03548935 (STEP 1), NCT03574597 (SELECT), NCT04184622 (SURMOUNT-1), NCT04881706 (Retatrutide Phase II), NCT00451282 (Tesamorelin Phase III), NCT02867267 (Thymosin Alpha-1 Sepsis).

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    Referenced Peptides

    bpc 157semaglutidetirzepatidethymosin alpha 1cjc 1295

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.